Related papers: Robust parametric modeling of Alzheimer's disease …

Dementia of Alzheimer's Type (DAT) is a complex disorder influenced by numerous factors, but it is unclear how each factor contributes to disease progression. An in-depth examination of these factors may yield an accurate estimate of…

Progressive neurodegenerative diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), exhibit complex, nonlinear trajectories that challenge deterministic…

Deep learning models have shown strong performance in diagnosing Alzheimer's disease (AD) using neuroimaging data, particularly 18F-FDG PET scans, with training datasets largely composed of North American cohorts such as those in the…

Attribution methods are an easy to use tool for investigating and validating machine learning models. Multiple methods have been suggested in the literature and it is not yet clear which method is most suitable for a given task. In this…

Accurate diagnosis and prognosis of Alzheimer's disease are crucial to develop new therapies and reduce the associated costs. Recently, with the advances of convolutional neural networks, methods have been proposed to automate these two…

Alzheimer's disease (AD) is the most common long-term illness in elderly people. In recent years, deep learning has become popular in the area of medical imaging and has had a lot of success there. It has become the most effective way to…

Neuropsychiatric symptoms (NPS) such as depression and apathy are common in Alzheimer's disease (AD) and often precede cognitive decline. NPS assessments hold promise as early detection markers due to their correlation with disease…

Longitudinal magnetic resonance imaging data is used to model trajectories of change in brain regions of interest to identify areas susceptible to atrophy in those with neurodegenerative conditions like Alzheimer's disease. Most methods for…

Alzheimer's disease (AD) is characterized by the progressive spread of pathology across brain networks, yet forecasting this cascade at the individual level remains challenging. We present a personalized graph-based dynamical model that…

Alzheimer's disease (AD), the predominant form of dementia, is a growing global challenge, emphasizing the urgent need for accurate and early diagnosis. Current clinical diagnoses rely on radiologist expert interpretation, which is prone to…

Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…

Early diagnosis of Alzheimer's disease is a challenge because the existing methodologies do not identify the patients in their preclinical stage, which can last up to a decade prior to the onset of clinical symptoms. Several research…

Accurately discriminating progressive stages of Alzheimer's Disease (AD) is crucial for early diagnosis and prevention. It often involves multiple imaging modalities to understand the complex pathology of AD, however, acquiring a complete…

Alzheimer's Disease is challenging to diagnose due to our limited understanding of its mechanism and large heterogeneity among patients. Neurodegeneration is studied widely as a biomarker for clinical diagnosis, which can be measured from…

Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration…

Alzheimers disease is a deadly neurological condition, impairing important memory and brain functions. Alzheimers disease promotes brain shrinkage, ultimately leading to dementia. Dementia diagnosis typically takes 2.8 to 4.4 years after…

We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219…

INTRODUCTION: Heterogeneity in the progression of Alzheimer's disease makes it challenging to predict the rate of cognitive and functional decline for individual patients. Tools for short-term prediction could help enrich clinical trial…

The current clinical diagnosis framework of Alzheimer's disease (AD) involves multiple modalities acquired from multiple diagnosis stages, each with distinct usage and cost. Previous AD diagnosis research has predominantly focused on how to…

Studies of Alzheimer's disease (AD) often collect multiple longitudinal clinical outcomes, which are correlated and predictive of AD progression. It is of great scientific interest to investigate the association between the outcomes and…